SynthesisBritish journal of cancer2005
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
Synthesis in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Pooled it
- Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.Cancer · 2009Pooled it
- The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.Breast cancer research and treatment · 2022Trial
- Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.Contraception · 2012Trial
- Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.British journal of cancer · 2024Article
- Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.Epidemiology (Cambridge, Mass.) · 2020Article
- Screening breast magnetic resonance imaging in women with hormone replacement therapy.European journal of medical research · 2018Article
- Hormonal contraception and breast cancer.Contraception · 2018Article
- Hormonal contraception and breast cancer.American journal of obstetrics and gynecology · 2018Article
- Article
- Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study.British journal of cancer · 2017Article
- Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?British journal of cancer · 2016Article
- Vaginal Estrogen Therapy for Patients with Breast Cancer.Geburtshilfe und Frauenheilkunde · 2013Article
- Breast cancer risk factors in a defined population: weighted logistic regression approach for rare events.Journal of breast cancer · 2013Article
- Hormonal therapy and risk of breast cancer in mexican women.PloS one · 2013Article
- Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.PloS one · 2013Article
- Exogenous estrogen protects mice from the consequences of obesity and alcohol.Menopause (New York, N.Y.) · 2012Article
- Hormone replacement therapy and the risk of breast cancer.Nature reviews. Clinical oncology · 2011Review
- Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women?Cancer causes & control : CCC · 2011Article
- Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Results from the Women's Health Initiative (WHI) trial support findings from observational studies that oestrogen-progestin therapy (EPT) use is associated with an increase in breast cancer risk. We conducted a meta-analysis using EPT-specific results from the Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC) pooled analysis and studies published since that report to obtain an overview of EPT use and breast cancer risk. We also assessed risk by histologic subtype of breast cancer, by schedule of the progestin component of EPT, and by recency of use. We estimate that overall, EPT results in a 7.6% increase in breast cancer risk per year of use. The risk was statistically significantly lower in US studies than in European studies - 5.2 vs 7.9%. There was a significantly higher risk for continuous-combined than for sequential EPT use in Scandinavian studies where much higher total doses of progestin were used in continuous-combined than in sequential EPT. We observed no overall difference in risk for lobular vs ductal carcinoma but did observe a slightly higher risk for current vs past EPT use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.